{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:36Z","timestamp":1791976536825,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008301"],"award-info":[{"award-number":["2020YFC2008301"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Food and Chemical Toxicology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.fct.2023.113926","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T17:49:26Z","timestamp":1688406566000},"page":"113926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen"],"prefix":"10.1016","volume":"178","author":[{"given":"Ling-jing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-shan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","article-title":"Allele and genotype frequencies of CYP2C9 in a Korean population","volume":"60","author":"Bae","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.fct.2023.113926_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.fpc.0000114759.08559.51","article-title":"Discovery of new potentially defective alleles of human CYP2C9","volume":"14","author":"Blaisdell","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"27","key":"10.1016\/j.fct.2023.113926_bib3","doi-asserted-by":"crossref","first-page":"17036","DOI":"10.1074\/jbc.273.27.17036","article-title":"Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase","volume":"273","author":"Bridges","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.fct.2023.113926_bib4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/aps.2013.123","article-title":"In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population","volume":"34","author":"Dai","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.fct.2023.113926_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/tpj.2013.2","article-title":"CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database","volume":"14","author":"Dai","year":"2014","journal-title":"Pharmacogenomics J."},{"issue":"13","key":"10.1016\/j.fct.2023.113926_bib6","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2217\/pgs.15.89","article-title":"Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient","volume":"16","author":"Dai","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.fct.2023.113926_bib7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.115.063412","article-title":"Identification and functional assessment of a new CYP2C9 allelic variant CYP2C9*59","volume":"43","author":"Dai","year":"2015","journal-title":"Drug Metabol. Dispos."},{"issue":"1","key":"10.1016\/j.fct.2023.113926_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jpm8010001","article-title":"Pharmacogenomics of CYP2C9: functional and clinical considerations","volume":"8","author":"Daly","year":"2017","journal-title":"J. Personalized Med."},{"issue":"3","key":"10.1016\/j.fct.2023.113926_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.105.091181","article-title":"Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians","volume":"315","author":"DeLozier","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-003-0606-2","article-title":"Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population","volume":"59","author":"Gaikovitch","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt.794","article-title":"Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system","volume":"102","author":"Grosser","year":"2017","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"9","key":"10.1016\/j.fct.2023.113926_bib12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00498250500256367","article-title":"Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13","volume":"35","author":"Guo","year":"2005","journal-title":"Xenobiotica; Fate Foreign Comp. Biol. Sys."},{"issue":"3","key":"10.1016\/j.fct.2023.113926_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.fct.2023.113926_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2478\/acph-2019-0032","article-title":"AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers - a pilot study in healthy volunteers","volume":"69","author":"Kapedanovska Nestorovska","year":"2019","journal-title":"Acta Pharm. (Zagreb, Croatia)"},{"issue":"2","key":"10.1016\/j.fct.2023.113926_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cpt.2008","article-title":"Clinical Pharmacogenetics implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update","volume":"109","author":"Karnes","year":"2021","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"6947","key":"10.1016\/j.fct.2023.113926_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature01817","article-title":"RhoG activates Rac1 by direct interaction with the Dock180-binding protein Elmo","volume":"424","author":"Katoh","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.fct.2023.113926_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/abbi.1998.0826","article-title":"Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen","volume":"357","author":"Klose","year":"1998","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.fct.2023.113926_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/aiht-2016-67-2754","article-title":"How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity","volume":"67","author":"Krasniqi","year":"2016","journal-title":"Arh. Hig. Rad. Toksikol."},{"issue":"5","key":"10.1016\/j.fct.2023.113926_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cpt.2549","article-title":"Warfarin dosing in patients with CYP2C9*5 variant alleles","volume":"111","author":"Lindley","year":"2022","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/clpt.2011.269","article-title":"Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism","volume":"91","author":"Liu","year":"2012","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.fct.2023.113926_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1254\/jphs.13189FP","article-title":"Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient","volume":"125","author":"Luo","year":"2014","journal-title":"J. Pharmacol. Sci."},{"issue":"41","key":"10.1016\/j.fct.2023.113926_bib23","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1021\/acs.biochem.7b00795","article-title":"Structural basis of single-nucleotide polymorphisms in cytochrome P450 2C9","volume":"56","author":"Maekawa","year":"2017","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.fct.2023.113926_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/pgs.15.40","article-title":"Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers","volume":"16","author":"Ochoa","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"19","key":"10.1016\/j.fct.2023.113926_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910206","article-title":"Insights into the genetic variations of human cytochrome P450 2C9: structural analysis, characterization and comparison","volume":"22","author":"Parikh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.fct.2023.113926_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.fct.2023.113926_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750108","article-title":"Kidney injury following ibuprofen and acetaminophen: a real-world analysis of post-marketing surveillance data","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"26","key":"10.1016\/j.fct.2023.113926_bib28","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1021\/acs.langmuir.2c00671","article-title":"Interfacial water in the SARS spike protein: investigating the interaction with human ACE2 receptor and in vitro uptake in A549 cells","volume":"38","author":"Singh","year":"2022","journal-title":"Langmuir"},{"key":"10.1016\/j.fct.2023.113926_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114784","article-title":"Integrative toxicogenomics: advancing precision medicine and toxicology through artificial intelligence and OMICs technology","volume":"163","author":"Singh","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.fct.2023.113926_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2023.131575","article-title":"Evaluation of biogenic nanosilver-acticoat for wound healing: a tri-modal in silico, in vitro and in vivo study","volume":"670","author":"Singh","year":"2023","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00204-023-03471-x","article-title":"Artificial intelligence and machine learning disciplines with the potential to improve the nanotoxicology and nanomedicine fields: a comprehensive review","volume":"97","author":"Singh","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.fct.2023.113926_bib32","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.2147\/DDDT.S268796","article-title":"Functional measurement of CYP2C9 and CYP3A4 allelic polymorphism on sildenafil metabolism","volume":"14","author":"Tang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.fct.2023.113926_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical Pharmacogenetics implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.fct.2023.113926_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","article-title":"Cytochrome P450 2C9-CYP2C9","volume":"20","author":"Van Booven","year":"2010","journal-title":"Pharmacogenetics Genom."},{"issue":"1","key":"10.1016\/j.fct.2023.113926_bib35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cpt.2613","article-title":"The impact of CYP2C9*11 allelic variant on the pharmacokinetics of phenytoin and (S)-Warfarin","volume":"112","author":"Wanounou","year":"2022","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.fct.2023.113926_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109799","article-title":"Enzymatic activity on valsartan of 38 CYP2C9 variants from the Chinese population","volume":"353","author":"Yuan","year":"2022","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.fct.2023.113926_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FPC.0000000000000364","article-title":"Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative","volume":"29","author":"Zajic","year":"2019","journal-title":"Pharmacogenetics Genom."},{"issue":"3","key":"10.1016\/j.fct.2023.113926_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clpt.2004.05.005","article-title":"Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose","volume":"76","author":"Zhao","year":"2004","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.fct.2023.113926_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphs.2017.08.006","article-title":"Function of 38 variants CYP2C9 polymorphism on ketamine metabolism in vitro","volume":"135","author":"Zheng","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.fct.2023.113926_bib40","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.biochi.2006.05.001","article-title":"On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study","volume":"88","author":"Zhou","year":"2006","journal-title":"Biochimie"}],"container-title":["Food and Chemical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278691523003289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278691523003289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:28:33Z","timestamp":1759530513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278691523003289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"alternative-id":["S0278691523003289"],"URL":"https:\/\/doi.org\/10.1016\/j.fct.2023.113926","relation":{},"ISSN":["0278-6915"],"issn-type":[{"value":"0278-6915","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen","name":"articletitle","label":"Article Title"},{"value":"Food and Chemical Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fct.2023.113926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113926"}}